Skip to main content Skip to main menu
UF Health University of Florida
Division of Gastroenterology, Hepatology & Nutrition Department of Medicine in the College of Medicine
Request a Patient Appointment
Lasheaka McClellan

Lasheaka McClellan,

Assistant Director Of Hepatology Clinical Research

Department: MD-GASTROENTERLOGY-LIVER
Business Phone: (352) 273-7285
Business Email: lasheaka.mcclellan@medicine.ufl.edu

On This Page

Grants

  1. A Phase 2b Double Blind, Placebo Controlled Study to Evaluate the Efficacy and Safety of CNP-104 in Adults with Primary Biliary Cholangitis

    Active

    Role:
    Other
    Funding:
    COUR PHARMACEUTICALS DEVELOPMENT

  2. Phase 3, Randomized, Controlled, Open-label Study to Compare the Efficacy and Safety of Bemnifosbuvir-Ruzasvir Fixed-dose Combination (BEM/RZR FDC) Versus Sofosbuvir-Velpatasvir Fixed-dose Combination (SOF/VEL FDC) in Subjects with Chronic Hepatitis C Virus (HCV) Infection

    Active

    Role:
    Other
    Funding:
    IQVIA RDS via ATEA PHARMACEUTICALS

  3. BIO89-100-132 A Phase 3 Study to Evaluate the Efficacy and Safety of Pegozafermin in Subjects with Compensated Cirrhosis due to Metabolic Dysfunction-Associated Steatohepatitis (MASH)

    Active

    Role:
    Other
    Funding:
    MEDPACE via 89BIO

  4. Prospective Observational Study on the Natural History of Alpha-1 Antitrypsin Deficiency Associated Liver Disease

    Active

    Role:
    Other
    Funding:
    OUTCOME SCIENCES via TAKEDA DEVELOPMENT CENTER AMERICAS INC

  5. Kowa K-808-2.01 A Phase 2, Randomized, Placebo-controlled,Parallel Group, Multi center 12-week Study with a 52-week Extensionto Evaluate Effi cacy and Safety of Two Doses of K-808 (Pemafi brate)in Subjects with Primary Biliary Cholangiti s with Inadequate Responseto Ursodeoxycholic Acid and/or Obeti cholic Acid Treatment

    Active

    Role:
    Other
    Funding:
    PHARMACEUTICAL RES ASSO via KOWA RESEARCH INSTITUTE

  6. A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Invasively Diagnosed Nonalcoholic Steatohepatitis (NASH)/Nonalcoholic Fatty Liver Disease (NAFLD)

    Role:
    Other
    Funding:
    SC LIVER RESEARCH CONSORTIUM via AKERO THERAPEUTICS

  7. D419CR00035 LIVER-R An Observational Mult-Center Study to Evaluate Real-World Treatment Outcomes of Durvalumab-based Regimens in Hepatobiliary Cancers

    Active

    Role:
    Other
    Funding:
    ICON CLINICAL RESEARCH INC via ASTRAZENECA

  8. Akero AK-US-001-0105 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects with Non-Cirrhotic Nonalcoholic Steatohepatitis (NASH) and Fibrosis

    Active

    Role:
    Other
    Funding:
    SC LIVER RESEARCH CONSORTIUM via AKERO THERAPEUTICS

Contact Details

Phones:
Business:
(352) 273-7285
Emails:
Business:
lasheaka.mcclellan@medicine.ufl.edu
Addresses:
Business Mailing:
PO Box 100272
 GAINESVILLE FL 32610
Business Street:
Room 2258
2004 Mowry Road
 GAINESVILLE FL 32610